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Pediatric venous thromboembolism in relation to
adults
Georgios Spentzouris, MDa Richard J. Scriven, MD,b Thomas K. Lee, MD,b and
Nicos Labropoulos, PhD, DIC, RVT,a Stony Brook, NY
Objective: This review was performed to analyze the current knowledge and controversies in the pathophysiology,
diagnosis, treatment, and outcomes of pediatric venous thromboembolism (VTE) compared with adults.
Methods: Searches of the MEDLINE database and manual searches of the references of selected articles were performed to
select reports for their relevance and quality of information on the similarities and differences in pathophysiology,
diagnosis, and treatment of VTE in children and adults.
Results: Symptomatic VTE incidence is reported at a rate of 0.07 in every 10,000 children, which is significantly lower
than the rate in adults. Pulmonary emboli in adolescents are rarely fatal, unlike in adults. VTE recurrence is also much
lower in children. Young age has been shown to be protective of VTE, whereas central venous catheters are very important
in pediatric venous thrombosis. The incidence of postthrombotic syndrome varies from 20% to 65%, with mild symptoms
in most children. Cerebral and visceral vein thrombosis may lead to severe morbidity and death. Some factors of
thrombophilia have a significant effect in the pediatric population; however, its overall significance is controversial. Most
data on VTE treatment are extrapolated from studies in adults. Children with acute VTE should be treated with
anticoagulation therapy. Treatment duration depends on the nature of the thrombosis and previous VTE events.
Conclusions: There is a paucity of prospective randomized studies with data determining not only the effect of VTE but
also the treatment options in children. Thrombophilia is a risk factor for pediatric VTE, but its significance has not been
thoroughly investigated. Guidelines specific to children for antithrombotic therapy, prophylaxis, and optimal duration
need re-evaluation and support by strong evidence. (J Vasc Surg 2012;55:1785-93.)
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dVenous thromboembolism (VTE) is an important and
relatively frequent cause of morbidity and death in adult
patients. Historically, venous thrombosis in children is a
rare condition. The incidence of VTE has increased over
the years because of the survival of children with historically
fatal conditions and advances in pediatric care. A recent
retrospective study in the United States covering a 7-year
span showed the rate of VTE ranged from 34 to 58 cases/
10,000 hospital admissions (P  .001), even suggesting
that this may be the new epidemic in pediatric tertiary care
hospitals.1 The goal of our study was to review and com-
pare diagnosis, treatment, and outcomes of VTE in pediat-
ric patients compared with adults.
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doi:10.1016/j.jvs.2011.07.047The estimated incidence of symptomatic VTE in chil-
ren from theCanadian Childhood Thrombophilia registry
n 1994 was 0.07/10,000 children, which is lower than
he 5.6 to 16 cases/10,000 adults per year.2-4 Later
tudies have reported higher pediatric VTE incidences,
anging from 4.9 to 21.9/10,000 hospital admissions,
ndicating a need for closer investigation5-8 or possibly
nder-representation of this patient population. VTE inci-
ence varies amongst different childhood age groups, with
he highest numbers in infants aged 1 to 23 months and in
eenagers, particularly teenaged girls.7,9 This latter obser-
ation can be explained by pregnancy-related deep vein
hrombosis (DVT), which also accounts for the 2.1-times
igher rate of DVT in women vs men (95% confidence
nterval [CI], 2.02-2.13).7
Unlike in adults, pulmonary emboli (PE) in adolescents
re rarely fatal and are seen twice as often in teenaged girls
han boys.9,10 The nonfatal outcome of PE in pediatric
atients can be explained by the near absence of chronic
ung disease, fewer cardiopulmonary comorbidities, and
heir greater pulmonary reserve. Surgery, especially ortho-
edic procedures, thrombophilia, and oral contraception
re significantly associated with PE (P  .5).9 Much of the
ata on incidence in pediatric VTE come from three main
egistries in Canada, Germany, and the Netherlands.2,11,12
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June 20121786 Spentzouris et alThe incidence of idiopathic VTE is only 5% in children and
1% in neonates compared with 40% in adults.2,4,13 Al-
though the neonatal period spans only 4 weeks, 12% of all
pediatric thrombi occur in neonates.4 Recurrent VTE is
reported to occur in approximately 3% of neonates and 8%
in older children.2,4,12,14
METHODS
AMEDLINE search of articles published from 1966 to
2011 was performed to select reports on the diagnosis,
treatment, and prevention of first-time and recurrent VTE.
The primary terms used were children and pediatrics, com-
bined with deep vein thrombosis, pulmonary embolism,
and venous thromboembolism. Secondary terms were cen-
tral venous line, sinovenous thrombosis, postthrombotic syn-
drome, prevention, treatment, anticoagulation, thrombolysis,
compression, mortality, morbidity, recurrence, portal vein,
renal vein, and hepatic vein. A manual search was also per-
formed from the references of the selected articles to identify
any important reports that had been missed.
With the exception of a few technical reports that were
important for determining the ability and quality of diag-
nosis, the rest of the articles were selected for their quality.
Owing to a lack of prospective randomized studies, most of
the larger cohorts giving an answer or at least an insight to
clinical problems were selected for this review. Limits for
the number of patients in each study were not used, with
the exception of case reports and small case series. We
selected most relevant articles from retrospective, cross-
sectional studies, randomized clinical trials, clinical regis-
tries, or prospective studies with acceptable follow-up ac-
cording to their subject.
Studies of VTE in children predominantly started after
the Canadian Registry of VTE in 1994, although there
were few isolated prior studies. A systematic review and
meta-analysis were not performed because this article cov-
ers a complex subject with a multitude of factors. There-
fore, pooling of data and separate analyses were not done.
Age ranges were not clearly identified in all the reports, and
thus definitions were omitted. However, most reports in-
cluded patients aged 18 years.
RESULTS
Pathophysiology. The incidence of VTE is signifi-
cantly lower in children compared with adults. Young age
has a protective role on developing thrombosis and could
be explained by the reduced capacity to generate throm-
bin,15,16 increased capacity of 2 macroglobulin to inhibit
thrombin,17 presence of a circulating anticoagulant at
birth,18-20 and enhanced antithrombotic potential by the
vessel wall.21,22 In addition, the vascular endothelium of
children has not accumulated damage from diseases such as
hypertension, diabetes, or hypercholesterolemia and there-
fore maintains its anticoagulant properties. In contrast to
adults, children may have not been exposed to acquired
thrombotic predictors, such as smoking or antiphospho-
lipid antibodies, but when present, the cumulative effect of
these predictors is much less. iVTE is divided into “provoked” and “unprovoked”
tiologies. Provoked etiologies include trauma, catheter
nsertion, and surgery. Unprovoked factors include
hrombophilia, idiopathy, and malignancy, although
alignancy may also be considered a provoking factor.
ost VTE events in children are secondary to conditions
uch as cancer, trauma/surgery, congenital heart disease,
ephrotic syndrome, and systemic lupus erythemato-
us.2,13,23-25 The most commonly thrombosed segments
n children are the femoropopliteal veins.5,26,27
One study demonstrated that children with the highest
isk for DVT before their admission were aged11 years.5
n hospitalized children, DVT most often is found in those
ged1 and11years.2,5 The information in the literature
s limited for the bimodal pattern of DVT in hospitalized
hildren. One explanation is that infants1 year with DVT
ave more serious conditions, and those children who are
ged 11 years are similar to the prehospitalized group.
The presence of a central venous line (CVL) in the
ediatric population is one of the most important risk
actors in the development of venous thrombosis.5,26,28
he introduction of a catheter in a vessel can cause throm-
osis by directly damaging the vessel wall,29 disrupting
lood flow, and subsequently occluding the vessel, intro-
ucing substances like total parenteral nutrition (TPN) that
amage endothelial cells,30 and by the thrombogenic na-
ure of the catheter material.31 The incidence of CVL-
elated thrombosis increases more in children with cancer
han in adults.5,32,33 Although CVLs are important for
ntensive or supportive care of children who require TPN,
hemotherapy, or antibiotic administration, more than half
f the DVT cases in children and 80% of newborn
ases occur in the upper extremity veins secondary to
VLs.2,11,13,28 Catheterization of the umbilical vessels is a
nique predictor of thrombosis in neonates, with an inci-
ence of approximately 13%.34 In a prospective cohort of
6 children with CVLs placed for 48 hours in an intensive
are unit (ICU), CVL-related DVT developed in 18%.35
ore impressively, the Prophylactic Antithrombin Re-
lacement in Kids with Acute Lymphoblastic Leukemia
reated with Asparaginase (PARKAA) study36 reported a
VT incidence of 37% by venography in children with
cute lymphoblastic leukemia treated with asparaginase
herapy.33
Cancer and sepsis are well-known risk factors for ve-
ous thrombosis, and recent literature supports the roles
hat they may play in VTE development in children37 or
dults.38-40 Alterations in the coagulation pathway were
eported in children with meningococcal infections and
steomyelitis associated with VTE in two small stud-
es.41,42 With respect to cancer, in adult patients who
resented with VTE, malignancy was diagnosed in 1.2%
o 4%.43-45 This rate is not clearly reported in children,
ut most likely should be lower than in adults. This
uggests other risks factors, such as mechanical obstruc-
ion, chemotherapy, and CVL, are significantly involved
n the development of VTE in this population.
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Volume 55, Number 6 Spentzouris et al 1787Diagnosis. Duplex ultrasound (DUS) imaging, venog-
raphy, computed tomography (CT), and magnetic reso-
nance imaging (MRI) can be used to diagnose venous
thrombosis in pediatric patients.2,13,32 Venography is con-
sidered the gold standard for the diagnosis of DVT, but it is
rarely used today33,46 because it is painful, invasive, and
peripheral venous access is difficult to obtain in children.
DUS imaging is the first modality that should be used
because it is safe, painless, inexpensive, portable, and readily
available. It is able to distinguish acute vs chronic thrombus
(Figs 1, A and B, and 2). Factors unique to the pediatric
population that may interfere with ultrasound imaging
include small diameter vessels, low pulse pressure, and the
presence of a CVL at the site of a thrombus (Fig 3, A and
B), which make the vein difficult to compress and subse-
quently hard to interpret.47 If the clinical suspicion for
Fig 1. Acute thrombosis of the common femoral vein in 2-year-
old boy is demonstrated by cross-sectional imaging of the femoral
vessels. A, The left panel shows a dilated common femoral vein
with echolucent luminal material. The right panel shows that the
common femoral vein is not compressible, despite the use pressure
that reduced the common femoral artery diameter by half. B, The
common femoral vein from the same patient is viewed with color
imaging. The vein is dilated, contains echolucent material, and has
absence of flow in contrast to normal flow in the adjacent common
femoral artery.venous thrombosis is high and DUS imaging is negative or iig 2. Chronic thrombosis of the common femoral vein is seen a
ear after it was diagnosed in a 4-month-old girl. Echogenic
aterial is seen in the lumen of the partially recanalized vein.
rregular flow channels are seen through the old thrombus in theig 3. Ultrasound imaging shows catheter-induced thrombosis
n the left arm of a 13-year-old girl. A, Acute thrombosis of the
asilic vein is seen around the catheter. No flow is seen in the
ilated lumen, with the catheter being very bright in the center and
he thrombus being echolucent around it. B, Acute thrombosis of
he subclavian vein is seen in the same patient. The catheter is seen
n the lumen with absence of flow in the vein.
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June 20121788 Spentzouris et alequivocal, then CT scan or MRI can be performed to
confirm the results. Unlike in children, Prandoni et al48
published a study in adults with suspected upper extremity
DVT that demonstrated a sensitivity of 100% and specificity
of 94% for compression ultrasound and color Doppler
ultrasound imaging for DVT.
It is critical to detect CVL-related thromboses in chil-
dren with objective imaging for many reasons. Evidence
shows that CVL-related thrombosis may lead to CVL-
related sepsis. In a meta-analysis, prophylactic unfraction-
ated heparin therapy reduced CVL-related VTE (relative
risk [RR], 0.43; 95% confidence interval [CI], 0.23-0.78)
and decreased bacterial colonization (RR, 0.18; 95% CI,
0.06-0.60).49 CVL-related thrombosis is one of the most
common sources for PE in children, which may be fa-
tal.4,32,50 Recurrent CVL-related thrombosis may result in
the loss of venous access that may be required for life-saving
interventions such as organ transplant.4,12,51 Finally, chil-
dren may have persistent right-to-left intracardiac shunts
where thrombus could embolize to the brain and cause a
stroke.4,32
The diagnosis of DVT in the subclavian, innominate, or
superior vena cava with DUS interrogation yields lower
sensitivity, and therefore, CT scan or MRI is used. Older
studies52 recommend venogram for detecting thrombi in
those locations, but today venograms are discouraged be-
cause of the invasiveness and the difficulty of access in
children. Pulmonary angiography is the gold standard for
diagnosing pulmonary embolus in adults, but in children it
can be difficult to get access or interpret the result, and it
can be dangerous because of its deleterious effects on renal
function. The ventilation/perfusion scan historically has
been the preferred method of documenting PE in pediat-
rics,46 but because this modality still requires intravenous
access and contrast, CT angiography is preferred. CT scan
is more frequently used because it is less invasive, relatively
quicker, and more accurate, although CT has not been
validated in children.53
Thrombophilia. The role of thrombophilic disorders
in childhood VTE still remains controversial. A recent
meta-analysis investigating the role of thrombophilia con-
sidered thrombophilia as an additional prothrombotic risk
factor in pediatric populations where thrombosis was asso-
ciated with underlying diseases.14 The combination of the
thrombophilia traits of antithrombin, protein C, and pro-
tein S produced the highest odds ratio (OR) and showed a
significant association with the first onset of pediatric VTE,
as well as recurrence. A similar correlation is seen in adult
studies, where patients with deficiencies in protein C, pro-
tein S, and antithrombin are considered to be at higher risk
for recurrent VTE.54 Current evidence supports that the
association of multiple prothrombotic defects, or the com-
bination of prothrombotic risk factors with acquired ones,
increases the risk of thrombosis not only in adults but also
in infants and children.55-61
However, other studies investigating the deficiencies of
antithrombin, protein C, and protein S, in addition to the
factor V Leiden and prothrombin gene mutations, found cegligible rates of thrombosis in children.62 A study of an
nselected cohort of children with VTE suggested that
nherited prothrombotic coagulation proteins do not con-
ribute significantly to the occurrence of pediatric VTE,
xcept in older children with spontaneous VTE.63 Another
tudy showed that children with VTE had a significantly
igher rate of combined genetic risk factors than their
arents,55 posing the question whether screening for ge-
etic risk factors in symptomatic patients is necessary.
Screening for thrombophilia is generally not recom-
ended because this knowledge does not aid in decision
aking about primary prophylaxis of VTE, and may result
n needless concerns for the parents and unnecessary treat-
ent. Specific subsets of patients may benefit from screen-
ng, including neonates with catheter-related thrombosis,
hildren with leukemia, and adolescents with unprovoked
hrombosis.14 More important than screening seems to be
ducation of the family to avoid behavioral prothrombotic
isk factors such as immobility, dehydration, sedentary life-
tyle, overweight/obesity, and smoking.64 The term “fam-
ly history of thrombosis” is not a well-defined variable, and
ow to use this information in assessing children for risk of
hrombophilia is not established. If the clinician and family
ecide to pursue thrombophilia testing because of a posi-
ive family history, consideration should be given to testing
he affected family members before testing the child.
Treatment. Pediatric studies are challenging to per-
orm, and as a result, antithrombotic therapy recommen-
ations are largely extrapolated from adult studies. Simi-
arly, most of the recommendations for treatment and
rophylaxis are derived from generalization of the evidence
rom remote pediatric and adult clinical trials. In 1995, the
merican College of Chest Physicians first proposed
ecommendations for the treatment and management of
ediatric DVT, and revisions followed.65 Anticoagulant
herapy with unfractionated heparin (UFH) or low-
olecular-weight heparin (LMWH) should be per-
ormed in children with first episode of VTE, with the
uration depending on the nature of the thrombosis.65
he use of routine systemic thromboprophylaxis for
hildren with CVLs was not advised.
Hospitalized children at greatest risk for DVT are con-
idered to be those admitted with severe respiratory, onco-
ogic, or infectious diseases, those receiving TPN, and
hose who require a prolonged ICU and hospital stay with
VL placement. These children may benefit from throm-
oprophylaxis.66 The American College of Chest Physi-
ians guidelines for antithrombotic therapy in children do
ot include the presence of inherited thrombophilia to
uide the duration of anticoagulant therapy,65 and there
re no evidence-based guidelines for thromboprophylaxis
n children with inherited thrombophilia.
Unlike in adult trauma patients where the incidence of
VT is as high as 21% without prophylaxis,67 prophylaxis
hile an inpatient may not be necessary in pediatric trauma
atients aged 13 years old without serious systemic dis-
ase.68 One study found the incidence of clinically signifi-
ant VTE after trauma in all pediatric patients was 0.06%,68
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Volume 55, Number 6 Spentzouris et al 1789and in a previous study, the incidence of PEwas 0.000069%
in the same population and 1.85% in children with spinal
cord injuries.28 Therefore, routine prophylaxis in all pedi-
atric patients should not be implemented unless all risk
factors are accounted for.
A randomized controlled trial reporting thrombopro-
phylaxis for CVL-related DVT was the Prophylaxis of
Thromboembolism in Kids Trial, which attempted to an-
swer the question of whether LMWH may prevent CVL-
related DVT.69 Although this study did not achieve suffi-
cient power to recommend routine thromboprophylaxis
for children with CVL in situ, it did show that LMWH is
safe to use in children.69 A randomized controlled trial
comparing an LMWH (reviparin sodium) with unfraction-
ated heparin or oral anticoagulation for the treatment of
VTE during childhood showed that LMWH was safe and
effective for the treatment of VTE in children.70 The study
was underpowered, but it demonstrated that symptomatic
recurrent thrombosis occurred after the treatment was
stopped and provided information for future studies on the
issues associated with therapy for VTE in children.
Thrombolytic regimens have been associated with
markedly decreased odds of postthrombotic syndrome
(PTS) at 18 to 24 months compared with standard antico-
agulation alone (OR, 0.018; 95% CI 0.001-0.483; P 
.02), suggesting that systemic or catheter-directed throm-
bolysis may safely and substantially reduce the risk of PTS in
children with occlusive lower extremity acute DVT.71
When a life-threatening or limb-threatening VTE is pres-
ent, thrombectomy is recommended. An aggressive treat-
ment of VTE with thrombolysis or surgical thrombectomy
is also recommended in children with severe sinovenous
thrombosis (SVT) who do not improve with initial antico-
agulation therapy. Tissue plasminogen activator has shown
efficacy in thrombolysis in venous thrombosis in pediatric
patients, but there are no clear indications for venous
thrombolysis in children. The only clear recommendations
mentioned by the Scientific Subcommittee on Perinatal
and Pediatric Thrombosis is that when concomitant hepa-
rin is used with thrombolytics, heparin should be adminis-
tered in prophylactic doses.72
Besides thrombolytic therapy, the use of inferior vena
cava filters has been described in children. The threshold of
placing an IVC filter in children is much higher because
there are concerns with IVC size and child growth, as well
as long-term complications. IVC filters are used in children
with venous thrombosis and contraindications to anticoag-
ulation, such as active bleeding,73,74 or failed anticoagula-
tion.74,75 IVC filter placement is restricted to children who
weigh 10 kg due to the size of the IVC and the available
filter sizes.
The placement and removal of retrievable IVC filters is
technically feasible and safe in children.76,77 Because of the
long-term complications associated with filter use, which
are similar in adults, retrievable filters should be removed as
soon as the risk of PE has resolved.76 The same study
showed that the most common reason for failure of re-
trieval of an IVC filter was endothelialization of the filter gook or struts.76 A retrospective review from a trauma
atabase demonstrated that children with filters in place
ad more severe injuries, as assessed by the Glasgow coma
cale, than those without a filter.73
Complications. The clinical sequelae of thrombosis
epend on the location of the VTE. Specific complications
nclude swelling, chylothorax, portal hypertension (which
eads to splenomegaly and varices), PE or pulmonary hy-
ertension, or both, renal vein thrombosis, cerebral vein
hrombosis, and superior vena cava syndrome.78-84 Para-
oxical emboli may occur in children with congenital
hunts.
Postthrombotic syndrome. PTS is a well-known
omplication of DVT that occurrs in 20% to 50% of adult
atients.85-88 PTS is defined as swelling, skin pigmentation,
ain, and ulceration of the limb secondary to DVT. At
resent, there are no properly validated outcome measure-
ents for PTS in children because there are very few studies
ith proper criteria and adequate follow-up. Although
reviously underestimated,4,89 PTS occurs in up to 65% of
hildren after venous thrombosis.51,90,91 Unlike in adults,
here the predictors of PTS are well described,86,92,93 risk
actors in children are limited due to lack of resolution of
he DVT by radiographic assessment (OR, 3.96; 95% CI,
.68-9.30), the number of vessels involved in the initial
VT (OR, 2.05; 95% CI, 1.52-2.77), and length of
ollow-up (OR, 1.22; 95% CI, 1.08-1.39).51 One of the
igher PTS incidences of 63% was given by a cross-sectional
tudy of 153 children at a median follow-up of 16
onths.51 It is important to note that the PTS was mild in
3% and moderate in 17%, with no one developing severe
igns and symptoms. Severe PTS is described in 9.3% of
dults at 5 years.85 However, long-term prospective data in
hildren are absent. PTS in the upper extremity is seen less
requently because there are more collaterals, almost non-
xistent reflux, and a shorter hydrostatic column compared
ith the lower extremities for both adults and children.
The low rate of recurrent VTE in children may imply
hat risk factors for pediatric DVT, such as CVL or under-
ying primary disorders, are transient in most cases. In
ddition, the higher rate of PTS described in children may
ndicate a lack of sufficient knowledge for treating DVT in
hildren. Although controversial, the presence of acquired
r congenital prothrombotic markers in children was not a
ignificant risk factor for development of PTS,51 as seen in
dults.
The established therapy for PTS includes the use of
ompression stockings, limb elevation, avoidance of pro-
onged standing, and early ambulation. Weight loss and
ild exercise have recently been investigated as therapy for
TS.94,95 As seen in adults, compliance with compression
tockings is problematic in children because they dislike
isplaying visible signs of a disability that make them vul-
erable to criticism from their peers. In addition, the diffi-
ulty in obtaining appropriately fitted garments in young
hildren and the need for resizing stockings due to the
rowth of the child makes compliance even harder.
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nal vein thrombosis is seen more often in newborns than
in older children. Most renal thrombi are unilateral and
present within the first 2 days of life, with hematuria,
proteinuria, thrombocytopenia, and a palpable abdomi-
nal mass.96,97 Renal vein thrombosis in children is a
multifactorial disease, and predisposing factors include
dehydration, sepsis, birth asphyxia, maternal diabetes,
traumatic delivery, congenital renal vein defects, and um-
bilical catheterization. Recent surveys suggest the impor-
tance of underlying prothrombotic conditions in renal vein
thrombosis, such as antithrombin, protein C and S defi-
ciency, and point mutations/substitutions in other coagu-
lation factors, with the factor V Leiden being the most
important.98-101 A recent retrospective trial showed that
larger perinatal kidneys had reduced long-term function,
suggesting more aggressive treatment should be imple-
mented.101
Anticoagulation and lytic therapy have both been sug-
gested for renal vein thrombosis in small studies, but treat-
ment recommendations still remain uncertain. A retrospective
case review of 10 years showed duration of anticoagulation
ranging from 6 to 14 days for intravenous heparin and from
14 days to 3 months for enoxaparin.102
Another form of thrombosis in pediatric patients is
portal vein thrombosis. The incidence of neonatal portal
vein thrombosis is controversial, ranging from 1% to 43%,
which may be explained by its silent nature and the exten-
sive use of umbilical venous catheters.103-105 Portal vein
thrombosis leads to portal hypertension,80 whichmayman-
ifest years later as splenomegaly without liver disease, rever-
sal of portal vein flow, and gastric and esophageal varices.79
Portal vein thrombosis is also associated with umbilical
sepsis. Major bleeding related to the varices may become
life-threatening.4,11
Stroke in neonates from SVT has been well de-
scribed47,106 and occurs more often than in adults.107 The
most frequently involved sinuses in neonatal SVT are the
superior sagittal and lateral sinuses, the major components
of the superficial venous system. Although the overall inci-
dence of SVT in childhood is 0.67/100,000, the incidence
in newborns is 41/100,000.106 Themost common presen-
tations of neonatal stroke are seizures and lethargy. Non-
neonates with SVT present frequently with focal neurologic
deficits or hemiparesis, whereas neonates show signs only
up to 25% of the time, explained by the immaturity of the
nervous system in the early days of life.47,106,108 Illnesses in
neonates that predispose to SVT include dehydration, sep-
sis, and head and neck disorders, including meningitis.47
Neonatal mortality from SVT is estimated at 12%, whereas
5% of neonates will have recurrent SVT.106
Mortality. Death after childhood stroke from SVT
occurs in 9% to 20%106,108 of children of all ages, represent-
ing all-cause mortality in children that includes cancer,
cardiac diseases, and sickle cell anemia. Prospective studies
of neonatal thrombosis report 5% to 18% all-cause mortal-
ity, with 50% of deaths due to thrombus formation.11,13A registry of noncentral nervous system VTE reported Oll-cause mortality of 15% to 17%, but DVT/PE related
ortality of only 2%.4
Limitations. There is limited published information
n the recurrence rates of VTE in neonates and on the
ncidence of PTS. In contrast to adults, where they can
erbalize pain, heaviness, swelling, cramps, and itching,
hese symptoms are more complicated to assess in younger
hildren because they have difficulty in conceptualizing.
hildren also have difficulties in verbalizing relative pain
everity or location; therefore, pain may be underestimated
n most of the studies.
Some studies indicate that thrombophilia serves as a
isk factor for thrombosis. However, the effect of each type
f thrombophilia alone on the outcome and recurrent risk
f thrombosis needs to be further investigated. Although
e have information on the epidemiology and risk factors
f pediatric renal vein thrombosis, evidence about optimal
herapy is very limited, suggesting that future trials are
equired. Until today, few clinical trials have been con-
ucted in pediatric VTE, in contrast to adults, resulting in
ajor gaps in pediatric evidence-based care. Nearly 80% of
ll drugs approved in the United States have not been
abeled for pediatric use, emphasizing the need for more
tudies to improve medical management in pediatric pa-
ients. Another barrier that must be overcome is the reluc-
ance to fund pediatric trials because they present complex
thical and practical issues that reduce feasibility and in-
rease costs compared with adult trials.
UTURE PERSPECTIVES
Prospective studies are needed to provide validated
uidelines for antithrombotic therapy and prophylaxis in
eonates and children. The Wells criteria cannot be applied
n pediatrics as the only method for diagnosis of VTE,
hich makes D-dimer testing a possible tool to improve
ccuracy. The incidence of PTS in children, the relationship
o various predictors, and the natural history of VTE need
o be delineated in the different age groups. The optimal
uration and dose of anticoagulation, the identity of pro-
hrombotic laboratory markers that predispose children to
hrombosis, and the effect of thrombolysis have not been
nvestigated adequately, which demands more research.
he role of thrombophilia in the development of pediatric
TE, isolated from secondary causes, has not been investi-
ated adequately. The biologic evaluation of genetic pre-
isposition for vascular events in children still remains
nclear, and future trials are also urgently needed.
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